Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

April 04, 2011 16:03 ET

Allezoe (ALZM): OTS and Research Collaborators to Attend and Present at International Society for Heart and Lung Transplantation (ISHLT)

FRISCO, TEXAS--(Marketwire - April 4, 2011) - Allezoe (OTCBB:ALZM) announces that members of the Organ Transport Systems ("OTS") leadership team will attend the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) April 13-16, 2011 in San Diego, California, where OTS collaborators will be presenting results from their latest preclinical studies. OTS plans to redefine human organ transplantation with its LifeCradle® device through better preservation and ease of use of the LifeCradle® in the current donor organ procurement process, at minimal costs. The preclinical research performed by the OTS collaborators further substantiates these plans.

The International Society for Heart and Lung Transplantation (ISHLT) meeting and scientific sessions are held annually to gather the most prominent thoracic surgeons, physicians, research scientist, engineers, and others involved in heart and lung transplantation to share their most recent findings for best practices and to review any new, emerging technologies with their peers from around the world.

This year, the cardiothoracic research team from University of Texas Southwestern Medical Center in Dallas, led by Dr. Michael E. Jessen, Professor & Chairman of the Dept. of Cardiothoracic Surgery, will be presenting, 'Retrograde Coronary Sinus Perfusion: An alternate approach for machine perfusion preservation of donor hearts for transplantation' authored by ML Cobert, LM West, ME Jessen, and M Peltz. Dr. Peltz will be presenting the paper at the ISHLT conference in San Diego. The study, which utilized an OTS LifeCradle® prototype, showed that the two preferred routes for perfusing the heart tissue in a transplant procedure both provided adequate oxygen and nutrients to maintain metabolism. Controlling the temperature so the hearts do not get too cold, as is the case when they are preserved on ice (the current standard method), and maintaining metabolism, prevents tissue damage during the preservation period and potentially gives the transplant team a more viable organ for the recipient.

Over the past several years OTS research collaborators have presented their pre-clinical research findings using the LifeCradle® HR donor heart preservation device at the ISHLT meetings showing that donor hearts can be better preserved by providing oxygen and nutrients to the heart tissue rather than just storing them on ice until they can be transplanted. This could potentially extend the preservation period and provide more time for delivery to recipients at greater distances. Currently, almost 10% of viable donated hearts are discarded because of time/geographical constraints, i.e. the donor hearts cannot be procured, transported, and then transplanted in the short 3-4 hours desirable for best outcomes.

During the ISHLT conference, Dr. Thomas D. Franklin, Jr., PhD, EVP of Research & Regulatory Affairs at OTS, will be meeting with members of OTS's Medical Advisory Board and its Clinical Trial Steering Committee that have been reviewing and guiding the OTS research and clinical plans over the past several years. The meetings will allow OTS's advisors to review the proposed clinical trial protocols and discuss ongoing research projects. OTS announced last week that it had received initial funding to continue preparations for clinical trials of its LifeCradle® device.

For more details please visit the OTS website at or the ISHLT website at

About Allezoe (ALZM)

Allezoe Medical Holdings, Inc. (ALZM) is the holding company for Organ Transport Systems, Inc. ("OTS") and for future acquisitions targeted to medical products, solutions and services. We believe it is possible to create value for shareholders as well as recipients of healthcare services at the same time, and we do so by seeking out the highest quality medical devices. OTS, headquartered in Frisco, Texas, is a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to redefine human organ transplantation through better preservation with its LifeCradle® product line.


This announcement is not an offer to sell any Allezoe ("ALZM") related securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of ALZM may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and includes, without limitation, statements regarding ALZM's plan of business operations, product research and development activities, anticipated revenues and expenses and potential contractual arrangements and obligations. Also, our management may make forward-looking statements orally to investors, analysts, the media and others. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact Information